-+ 0.00%
-+ 0.00%
-+ 0.00%

Caribou reports durable responses in phase 1 CaMMouflage trial of CB-011 CAR-T in relapsed multiple myeloma

PUBT·06/11/2026 12:02:16
Listen to the news
Caribou reports durable responses in phase 1 CaMMouflage trial of CB-011 CAR-T in relapsed multiple myeloma
  • Caribou Biosciences disclosed longer-follow-up Phase 1 CaMMouflage data for off-the-shelf BCMA CAR-T candidate CB-011 in relapsed or refractory multiple myeloma.
  • Results were scheduled for oral presentation at the European Hematology Association annual meeting on June 14, 2026.
  • Patients given a single infusion showed deep responses that held up over time in a heavily pretreated, BCMA-naïve group.
  • A case study indicated activity in a patient previously treated with an approved BCMA CAR-T, with an early complete response ongoing at cutoff.
  • Initial dose-expansion readouts in BCMA-naïve and BCMA-exposed patients are expected in H2 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Caribou Biosciences Inc. published the original content used to generate this news brief on June 11, 2026, and is solely responsible for the information contained therein.